In conclusion, FCGR3A is a biomarker with potential prognostic value for PCa, which can predict the survival of PCa patients and provide a new basis for rational administration in clinical of PCa patients.With the development of new technologies, FCGR3A is expected to become a new breakthrough point for potent drugs. This evidence concerns the gene FCGR3A and posterior cortical atrophy.